3-氟环己胺 | 1273566-51-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 中文名称: 3-氟环己胺
• 英文名称: 3-Fluorocyclohexanamine
• 英文别名: 3-fluorocyclohexan-1-amine
• CAS: 1273566-51-0
• 化学式: C₆H₁₂FN
• mdl: MFCD18791204
• 分子量: 117.166
• InChiKey: ZPZKJQKFLQCCMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  吲哚-2-羧酸 、 异氰环已烷 、 3-氟环己胺 、 2-氯苯甲醛 以 甲醇 为溶剂， 反应 1.0h， 生成 N-[1-(2-chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl]-N-(3-fluorophenyl)-1H-indole-2-carboxamide
  参考文献：
  名称：

  [EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  [FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION

  摘要：

  提供了一种治疗具有IDH1/2突变等特征的癌症的方法，包括向需要的受试者施用本处描述的化合物。

  公开号：

  WO2013107405A1

文献信息

• [EN] PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO 3,4-B! PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASE DE TYPE 4 (PDE4)
  申请人：GLAXO GROUP LTD

  公开号：WO2005090348A1

  公开（公告）日：2005-09-29

  The invention provides a compound of formula (I) or a salt thereof: formula (I) wherein W is Ar, -CR4R5Ar or a group (y) or (y1), wherein Ar is (x) or (z): formulae (x), (z), (y), (y1) R1 is C1-4alkyl, C1-3fluoroalkyl or CH2CH2OH. R2 is C2-6alkyl, C3-6cycloalkyl or -(CH2)n4-C3-6cycloalkyl; and R3 is optionally substituted C3-8cycloalkyl, optionally substituted mono unsaturated C5-7cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc) (in which Y is O, S, SO2, or NR10), or a bicyclic group (ee): formulae (aa), (bb), (cc), (ee). The invention also relates to the use of the compounds in therapy as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis.

  该发明提供了式(I)的化合物或其盐：式(I)其中W是Ar，-CR4R5Ar或(y)或(y1)的基团，其中Ar是(x)或(z)：式(x)，(z)，(y)，(y1)；R1是C1-4烷基，C1-3氟代烷基或CH2CH2OH；R2是C2-6烷基，C3-6环烷基或-(CH2)n4-C3-6环烷基；R3是可选取代的C3-8环烷基，可选取代的单不饱和C5-7环烯基，可选取代的杂环基(aa)，(bb)或(cc)(其中Y是O，S，SO2或NR10)，或双环基(ee)：式(aa)，(bb)，(cc)，(ee)。该发明还涉及将该化合物用于治疗作为磷酸二酯酶IV(PDE4)的抑制剂，并/或用于治疗和/或预防炎症和/或过敏性疾病，例如慢性阻塞性肺疾病(COPD)，哮喘，类风湿性关节炎或过敏性鼻炎。
• [EN] ELECTRON BUFFERING MATERIALS, ELECTRON TRANSPORT MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME<br/>[FR] MATÉRIAUX TAMPON D'ÉLECTRONS, MATÉRIAUX DE TRANSPORT D'ÉLECTRONS ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE LES COMPRENANT
  申请人：ROHM & HAAS ELECT MATERIALS KOREA LTD

  公开号：WO2017073942A1

  公开（公告）日：2017-05-04

  The present disclosure relates to an electron buffering material, and an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an electron transport zone and an electron buffering layer between the light-emitting layer and the second electrode. The organic electroluminescent device comprising the electron buffering material of the present disclosure has low driving voltage, excellent luminous efficiency, and long lifespan.

  本公开涉及一种电子缓冲材料，以及包括第一电极、面向第一电极的第二电极、位于第一电极和第二电极之间的发光层、以及位于发光层和第二电极之间的电子传输区和电子缓冲层的有机电致发光器件。采用本公开的电子缓冲材料制备的有机电致发光器件具有低驱动电压、优异的发光效率和长寿命。
• Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors
  申请人：ALLEN David George

  公开号：US20080175914A1

  公开（公告）日：2008-07-24

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE 4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及公式（I）的化合物或其盐： 其中： R1是C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基; R2是氢原子（H），甲基或C1氟烷基; R3是可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚公式（aa），（bb）或（cc）的可选取代的杂环基; 其中n1和n2独立地为1或2; Y是O，S，SO2或NR10; 或R3是双环基（dd）或（ee）： 其中X是NR4R5或OR5a。 该化合物是磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了公式（I）的化合物或其药学上可接受的盐的用途，用于制造治疗和/或预防哺乳动物，如人类的炎症性和/或过敏性疾病的药物，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors
  申请人：Allen George David

  公开号：US20080021058A1

  公开（公告）日：2008-01-24

  The invention provides a compound of formula (I) or a salt thereof: wherein W is Ar, —CR 4 R 5 Ar or a group (y) or (y1), wherein Ar is (x) or (z): R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl or —CH 2 CH 2 OH. R 2 is C 2-6 alkyl, C 3-6 cycloalkyl or —(CH 2 ) n 4-C 3-6 cycloalkyl; and R 3 is optionally substituted C 3-8 cycloalkyl, optionally substituted mono-unsaturated-C 5-7 cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc) (in which Y is O, S, SO 2 , or NR 10 ), or a bicyclic group (ee): These compounds are PDE4 inhibitors.

  本发明提供了式(I)的化合物或其盐：其中，W为Ar，—CR4R5Ar或(y)或(y1)基团，其中Ar为(x)或(z)：R1为C1-4烷基，C1-3氟烷基或—CH2CH2OH；R2为C2-6烷基，C3-6环烷基或—(CH2)n4-C3-6环烷基；R3为可选取代的C3-8环烷基，可选取代的单不饱和C5-7环戊烯基，可选取代的杂环基(aa)、(bb)或(cc)（其中Y为O、S、SO2或NR10），或双环基(ee)。这些化合物是PDE4抑制剂。
• [EN] N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA<br/>[FR] DÉRIVÉS DE N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE ET DE N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS D'IRAK4 POUR LE TRAITEMENT DE L'ASTHME
  申请人：ASTRAZENECA AB

  公开号：WO2022122876A1

  公开（公告）日：2022-06-16

  The present application relates to a compound of Formula (A),wherein R1 is selected from Formula (II) and Formula (III) and R2 is selected from Formula (IV), Formula (V) and Formula (VI) as IRAK4 inhibitors for use in methods of treatment of e.g. asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases, and autoinflammatory/autoimmune diseases such as e.g. systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present invention are e.g.: • N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(imidazo[1,2-b]pyridazin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide, and • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide derivatives. An exemplary compound of the present invention is e.g. N- (imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-1-methyl-2-oxo-1- azaspiro[4.5]decan-8-yl)-2H-indazole-5-carboxamide (Example 1): Formula (VII).

  本申请涉及一种化合物，其化学式为(A)，其中R1从化学式(II)和化学式(III)中选择，R2从化学式(IV)、化学式(V)和化学式(VI)中选择，作为IRAK4抑制剂用于治疗哮喘和慢性阻塞性肺疾病(COPD)、癌症、炎症性疾病以及自身免疫性疾病，如系统性红斑狼疮、类风湿性关节炎、肌炎、干燥综合症、系统性硬化症、痛风、子宫内膜异位症和银屑病等。本发明的优选化合物包括：•N-(咪唑并[1,2-b]吡嗪-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(咪唑并[1,2-b]吡嗪-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺和•N-(吡唑并[1,5-a]嘧啶-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺衍生物。本发明的一种示例化合物是N-(咪唑并[1,2-b]吡嗪-3-基)-6-甲氧基-2-((5r,8r)-1-甲基-2-氧代-1-氮杂螺[4.5]癸烷-8-基)-2H-吲唑-5-羧酰胺(实例1)：化学式(VII)。